Table 3: Therapeutic applications of bone marrow-derived MSCs in liver cirrhosis patients.
Cell type | Dose | Route | Sample size (n) | Outcome | Reference |
BM-MSC | Single median dose/unspecified | Intrahepatic and intrasplenic | 40 | Increased serum albumin; Decreased CPS, MELD score, bilirubin and ascites | [40] |
BM-MSC | Single median dose/30-40 × 106 | Peripheral vein | 4 | Improved liver function and Decreased MELD score | [48] |
BM-MSC | Single median dose/31.73 × 106 | Peripheral or the portal vein | 8 | Increased serum albumin; Decreased MELD score, serum creatinine, prothrombin, and bilirubin | [10] |
BM-MSC | Single median dose/unspecified | Hepaic artery | 572 | Increased serum albumin; Decreased MELD score and serum bilirubin | [54] |
BM-MSC | Single median dose/1 × 106 per kg body weight | Intravenous | 25 | Improved serum albumin; Decreased prothrombin, bilirubin and MELD score | [55] |
BM-MSC | Single median dose/10 × 106 | Intrasplenic | 20 | Increased serum albumin; Decreased serum bilirubin, AST, ALT, prothrombin and INR | [56] |
BM-MSC | Single median dose/1.9 × 108 | Peripheral vein | 27 | No significant improvement | [9] |